Skip to main
IVA
IVA logo

Inventiva S.A. (IVA) Stock Forecast & Price Target

Inventiva S.A. (IVA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Inventiva SA is focused on developing its lead product candidate, lanifibranor, as a potential treatment for non-alcoholic steatohepatitis (NASH), a significant unmet medical need, with evidence suggesting its benefits extend to high-risk subgroups such as those with Type 2 Diabetes. The positive impact of lanifibranor on metabolic markers and weight trajectory, alongside a potential role as a combination treatment option with other therapies, positions the company favorably within the evolving NASH therapeutic landscape. Additionally, management's optimistic outlook regarding lanifibranor's incremental benefits over existing treatments may enhance its market penetration and accelerate adoption, ultimately contributing to a stronger financial performance for Inventiva.

Bears say

Inventiva SA, a biopharmaceutical company focused on developing drugs for NASH and other conditions, reported a substantial net loss of €175.9 million, translating to €1.62 per share, which raises concerns about its financial stability. The company's primary clinical program, lanifibranor, is currently in Phase III development, and any efficacy or safety issues that arise could significantly negatively impact share performance. Additionally, high turnover in key regulatory positions, particularly the CEO and CMO, alongside dependence on research partnerships for revenue, presents further risks to the company’s operational continuity and future profitability.

Inventiva S.A. (IVA) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inventiva S.A. (IVA) Forecast

Analysts have given Inventiva S.A. (IVA) a Buy based on their latest research and market trends.

According to 6 analysts, Inventiva S.A. (IVA) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inventiva S.A. (IVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.